These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30575061)

  • 21. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Information-based sample size re-estimation in group sequential design for longitudinal trials.
    Zhou J; Adewale A; Shentu Y; Liu J; Anderson K
    Stat Med; 2014 Sep; 33(22):3801-14. PubMed ID: 24797715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling lesion counts in multiple sclerosis when patients have been selected for baseline activity.
    Morgan CJ; Aban IB; Katholi CR; Cutter GR
    Mult Scler; 2010 Aug; 16(8):926-34. PubMed ID: 20562161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A practical comparison of blinded methods for sample size reviews in survival data clinical trials.
    Todd S; Valdés-Márquez E; West J
    Pharm Stat; 2012; 11(2):141-8. PubMed ID: 22337635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blinded sample size re-estimation in superiority and noninferiority trials: bias versus variance in variance estimation.
    Friede T; Kieser M
    Pharm Stat; 2013; 12(3):141-6. PubMed ID: 23509095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials.
    Verhey LH; Signori A; Arnold DL; Bar-Or A; Sadovnick AD; Marrie RA; Banwell B; Sormani MP
    Neurology; 2013 Oct; 81(14):1215-21. PubMed ID: 23966255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On sample size estimation and re-estimation adjusting for variability in confirmatory trials.
    Wu PS; Lin M; Chow SC
    J Biopharm Stat; 2016; 26(1):44-54. PubMed ID: 26378970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size calculation and re-estimation based on the prevalence in a single-arm confirmatory diagnostic accuracy study.
    Stark M; Zapf A
    Stat Methods Med Res; 2020 Oct; 29(10):2958-2971. PubMed ID: 32299298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Power analyses for negative binomial models with application to multiple sclerosis clinical trials.
    Rettiganti M; Nagaraja HN
    J Biopharm Stat; 2012; 22(2):237-59. PubMed ID: 22251172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Group sequential, sample size re-estimation and two-stage adaptive designs in clinical trials: a comparison.
    Shih WJ
    Stat Med; 2006 Mar; 25(6):933-41. PubMed ID: 16220505
    [No Abstract]   [Full Text] [Related]  

  • 32. Blinded sample size re-estimation for comparing over-dispersed count data incorporating follow-up lengths.
    Igeta M; Matsui S
    Stat Med; 2022 Dec; 41(29):5622-5644. PubMed ID: 36148560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample size calculation for clinical trials with correlated count measurements based on the negative binomial distribution.
    Li D; Zhang S; Cao J
    Stat Med; 2019 Dec; 38(28):5413-5427. PubMed ID: 31652010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient adaptive designs with mid-course sample size adjustment in clinical trials.
    Bartroff J; Lai TL
    Stat Med; 2008 May; 27(10):1593-611. PubMed ID: 18275090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.
    Nicholas R; Straube S; Schmidli H; Schneider S; Friede T
    Mult Scler; 2011 Oct; 17(10):1211-7. PubMed ID: 21586489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptive, group sequential and decision theoretic approaches to sample size determination.
    Mehta CR; Patel NR
    Stat Med; 2006 Oct; 25(19):3250-69; discussion 3297-301, 3302-4, 3313-4, 3326-47. PubMed ID: 16927402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A free gift: an adaptive strategy in a single-arm trial using an exact test through the binomial distribution.
    Wang J
    J Biopharm Stat; 2012; 22(6):1127-36. PubMed ID: 23075012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI-based clinical trials in relapsing-remitting MS: new sample size calculations based on a longitudinal model.
    Altman RM; Petkau AJ; Vrecko D; Smith A
    Mult Scler; 2012 Nov; 18(11):1600-8. PubMed ID: 22495948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the inappropriateness of an EM algorithm based procedure for blinded sample size re-estimation.
    Friede T; Kieser M
    Stat Med; 2002 Jan; 21(2):165-76. PubMed ID: 11782057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A flexible mixed-effect negative binomial regression model for detecting unusual increases in MRI lesion counts in individual multiple sclerosis patients.
    Kondo Y; Zhao Y; Petkau J
    Stat Med; 2015 Jun; 34(13):2165-80. PubMed ID: 25784219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.